Mentor Capital Inc. - 15(c) 2-11

Mentor Capital, Inc and CI Companies

66 Days Left on $1 Call

About Mentor Capital About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance The Investor's Corner 2009 Annual Financials (Subject to Audit Adjustments) 2008 Audit 15(c) 2-11 Analysts' Coverage $5 / Share - Sr. Securities Analyst Cancer Imm Index Information Visit Portfolio Companies

Mentor Capital 15(c) 2-11

All PDF Documents will open a new browser window

Mentor Capital Inc. Disclosure Statement Pursuant To Rule 15(c) 2-11

The Mentor Capital Cancer Immunotherapy Index^©

Our Science Explained

For Email Marketing you can trust

Site Search

Home

Changing Assets & Acquisitions

Chairman's Letters

◦	Welcome to the Team Leading the Cancer Fight

◦	List of All Releases
◦	Mentor Capital Extends Funding to Leading-Edge Cancer Therapy Companies
◦	Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science
◦	Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index.
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	University Agreement Indicates Broad Cancer Application for QI Treatment
◦	New Lab, Filings and JV Talks
◦	MNTR Presents In NYC
◦	Start of FDA Trials
◦	QI Announces MNTR
◦	MNTR Acquires First 20% of QI
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

All PDF documents will open a new browser window

©2010 Mentor Capital Inc. | All Rights Reserved

Safe Harbor Statement Site Map